Additional file 4 of Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Additional file 4: Table S1. Table listing Ribociclib IC50 in each of the breast cancer cell lines. ER, AR and HER2 levels, as measured by RPPA, also included for reference.

附加文件4：表S1。本表收录了各乳腺癌细胞系中瑞博西尼（Ribociclib）的半数抑制浓度（IC50），同时附带收录通过反向蛋白阵列（Reverse Phase Protein Array, RPPA）检测得到的雌激素受体（Estrogen Receptor, ER）、雄激素受体（Androgen Receptor, AR）与人表皮生长因子受体2（Human Epidermal Growth Factor Receptor 2, HER2）水平以供参考。